Kalaris Therapeutics (NASDAQ:KLRS) Trading 7% Higher – Here’s What Happened

Kalaris Therapeutics Inc. (NASDAQ:KLRS) traded up 7% during trading on Monday . The company traded as high as $4.98 and last traded at $4.76. 283,792 shares changed hands during mid-day trading, an increase of 8% from the average session volume of 261,732 shares. The stock had previously closed at $4.45.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on KLRS shares. Wall Street Zen upgraded shares of Kalaris Therapeutics to a “hold” rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a “sell (e)” rating on shares of Kalaris Therapeutics in a research report on Wednesday, October 8th. Raymond James Financial started coverage on shares of Kalaris Therapeutics in a research report on Tuesday, September 2nd. They set a “strong-buy” rating for the company. Finally, Piper Sandler set a $3.00 price target on shares of Kalaris Therapeutics and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $3.00.

Kalaris Therapeutics Stock Performance

The firm’s fifty day simple moving average is $4.19.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its earnings results on Wednesday, August 13th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10).

Hedge Funds Weigh In On Kalaris Therapeutics

An institutional investor recently bought a new position in Kalaris Therapeutics stock. XTX Topco Ltd acquired a new stake in Kalaris Therapeutics Inc. (NASDAQ:KLRS) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 24,234 shares of the company’s stock, valued at approximately $65,000. XTX Topco Ltd owned 0.13% of Kalaris Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.